ABOS
Price
$2.85
Change
-$0.31 (-9.81%)
Updated
Sep 9 closing price
Capitalization
205.74M
67 days until earnings call
Intraday BUY SELL Signals
EVAX
Price
$3.12
Change
-$0.17 (-5.17%)
Updated
Sep 10, 11:21 AM (EDT)
Capitalization
29.5M
70 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs EVAX

ABOS vs EVAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABOS vs. EVAX commentary
Sep 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and EVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2026
Stock price -- (ABOS: $2.85 vs. EVAX: $3.29)
Brand notoriety: ABOS and EVAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 102% vs. EVAX: 58%
Market capitalization -- ABOS: $205.74M vs. EVAX: $29.5M
ABOS [@Biotechnology] is valued at $205.74M. EVAX’s [@Biotechnology] market capitalization is $29.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $132.08B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileEVAX’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • EVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABOS and EVAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while EVAX’s TA Score has 6 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 6 bearish.
  • EVAX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, EVAX is a better buy in the short-term than ABOS.

Price Growth

ABOS (@Biotechnology) experienced а -8.06% price change this week, while EVAX (@Biotechnology) price change was +7.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.96%. For the same industry, the average monthly price growth was -1.95%, and the average quarterly price growth was +2729.16%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 16, 2026.

EVAX is expected to report earnings on Nov 19, 2026.

Industries' Descriptions

@Biotechnology (-3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($206M) has a higher market cap than EVAX($29.5M). ABOS YTD gains are higher at: 35.071 vs. EVAX (-31.027). EVAX has higher annual earnings (EBITDA): -8.24M vs. ABOS (-100.54M). ABOS has more cash in the bank: 110M vs. EVAX (14M). EVAX has less debt than ABOS: EVAX (7.11M) vs ABOS (31.6M). EVAX has higher revenues than ABOS: EVAX (7.49M) vs ABOS (0).
ABOSEVAXABOS / EVAX
Capitalization206M29.5M698%
EBITDA-100.54M-8.24M1,220%
Gain YTD35.071-31.027-113%
P/E RatioN/AN/A-
Revenue07.49M-
Total Cash110M14M786%
Total Debt31.6M7.11M445%
TECHNICAL ANALYSIS
Technical Analysis
ABOSEVAX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
ABOS
Daily Signal:
Gain/Loss:
EVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VUIAX94.36N/A
N/A
Vanguard Utilities Index Adm
LCBVX44.21N/A
N/A
ClearBridge Large Cap Value R
BIVSX18.64N/A
N/A
Invenomic Super Institutional
THPBX25.84-0.13
-0.50%
BNY Mellon Balanced Opportunity J
FCGPX21.45-0.33
-1.52%
NYLIM PineStone Global Equity Class P

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-9.81%
CCXI - ABOS
48%
Loosely correlated
-2.94%
NKTX - ABOS
42%
Loosely correlated
-9.91%
RCKT - ABOS
42%
Loosely correlated
-2.16%
EDIT - ABOS
41%
Loosely correlated
-8.58%
BCYC - ABOS
40%
Loosely correlated
-4.19%
More